 |
| Who's Online |
There are currently, 56 guest(s) and 9 member(s) that are online.
You are an Anonymous user. You can register for free. | |
| |
UK med-mj researchThis page collects news stories about the official medical cannabis trials conducted in the UK. These large scale trials used whole plant extracts delivered under the tongue using aerosols sprays. The trials tested different strains of cannabis, grown at a secure location by GW Pharmaceuticals, to see which strain had the most benefit for each medical condition.
|
|
News stories
 |
Posted by norml on Monday, September 11 2006 (2407 reads)
|
 Source: BBC Wednesday 6 September 2006
The first cannabis-based medication for MS has been filed for approval by British regulators.
GW Pharmaceuticals' Sativex, an under-the-tongue spray, can now be given on a named-patient basis.
But the company is applying to regulators across Europe for a licence to make it more widely available.
|
|
|
(Read More | 1736 bytes |   | Score: 5)
|
|
|
|
Posted by norml on Saturday, February 12 2005 (3773 reads)
|
Issue 2485, 05 February 2005, page 38.
By Clare Wilson
The drug can be a lifeline, and a fortunate few may soon get it on prescription. But why has it taken so long?
|
|
|
(Read More | 13676 bytes | | Score: 4.42)
|
|
|
|
Posted by norml on Saturday, February 12 2005 (3146 reads)
|
Wall Street Journal (US), Tuesday 08 Feb 2005
Mouth Spray Wins Preliminary Approval -- U.K. and U.S. Tests Loom
As some popular painkillers come under fire for causing dangerous side effects, an often-shunned alternative is gaining legitimacy in pain relief: cannabis.
Medical marijuana has been winning legal endorsement through the efforts of a British pharmaceutical firm. GW Pharmaceuticals of Salisbury, England, has spent years developing and promoting a cannabis-based mouth spray that
the company claims eases severe pain and muscle stiffness without causing a psychotropic high. Winning the backing of health authorities has been an uphill battle, but Canadian officials recently gave it preliminary approval for treatment of neuropathic pain in multiple sclerosis sufferers.
|
|
|
(Read More | 6945 bytes | | Score: 5)
|
|
|
|
Posted by drstuey on Friday, December 03 2004 (4493 reads)
|
Major blow for medical cannabis worldwide. Approval not likely for two years!
Sativex, the under the tongue spray of whole plant-extracts has been denied approval for sale by UK regulators. The Committee on Safety of Medicines (CSM), an advisory body to the Medicines and Healthcare products Regulatory Agency (MHRA), noted that Sativex met the criteria for quality and safety, but they felt that the evidence for efficacy was not strong enough. They recognised that Sativex had a clinical effect on spasicity in multiple sclerosis, but they questioned the clinical "relevance" of the effect for patients.
The news was greeted with surprise and dismay by scientists involved with the trials and by patients groups who felt that the evidence was so strong that Sativex must be approved. The UK regulators had previously forced GW Pharmacueticals to only supply a single clinical study to support their application, rather than looking at all the evidence.
GW Pharmacueticals are able to appeal the decision, but this will take six months. They have started the trial that the regulators have asked for but that will not be finished until the end of 2005 at the earliest.GW are pinning their hopes on selling Sativex in countries where cannabis is allowed as medicine such as Canada, but the GW share price fell by a quarter at the news.
The decision is bad news for New Zealand cananbis patients as well since the Ministry of Health justifies stalling on medical cannabis by the fact that Sativex has not been approved yet.
|
|
|
(Read More | 1783 bytes | | Score: 5)
|
|
|
|
Posted by drstuey on Friday, November 28 2003 (4194 reads)
|
GW Pharmaceuticals, the UK company developing a cannabis spray medicine called Sativex, announced to shareholders that government approval for Sativex is now unlikely this year and could be as late as autumn 2004.
It is not only a blow for patients in the UK who hoped to see Sativex on prescription this year, but for patients in New Zealand, since Minister of Health Annette King has said that no decision on cannabis as medicine will be made in Aotearoa until the UK medicines authority makes a decision.
GW are not only concerned about the delay, but the company is also growing less confident that the Government's medicines regulator will approve Sativex for all the uses it originally requested. While use for MS seems certain to be approved, the application to use Sativex for neuropathic pain could be rejected until more trial results are available later next year.
 Read all about GW, Sativex and the UK clinical trials
|
|
|
(Read More | 3658 bytes | | Score: 5)
|
|
|
|
Posted by drstuey on Thursday, November 27 2003 (2838 reads)
|
ProgTeeTotall writes:
"More details of the UK clinical trials emerged in New Scientist (15/11/03). Andy Coughlin summarises the outcome of the Lancet paper on multiple sclerosis and the analgesic effects of medical cannabis administered in a double-blind trial. Coughlin also notes different situations related to the medical marijuana debate in the United States, Canada and the United Kingdom"
|
|
|
(Read More | 520 bytes | | Score: 0)
|
|
|
|
Posted by drstuey on Friday, November 07 2003 (3760 reads)
|
Results from the world's largest study into the medical effects of cannabis have confirmed that the drug can reduce pain and improve the lives of people with multiple sclerosis.
The three-year study, published in the british medical journal the Lancet, is the first proper clinical appraisal of whether cannabis-derived drugs can help treat MS.
The UK National Multiple Sclerosis Society welcomed the study, while Green MP Nandor Tanczos said that it is no longer good enough for the Government to say it is waiting for the evidence.
http://www.nationalmssociety.org/pdf/research/Research-2003Nov6.pdf
 07/11/03 No more excuses for Minister of Health
|
|
|
(Read More | 2480 bytes | | Score: 5)
|
|
|
|
Posted by drstuey on Wednesday, August 20 2003 (3079 reads)
|
The Guardian, UK
Wednesday 20 August 2003
Cannabis is to be used to treat pain relief after surgery in 35 hospitals across the country under a government-funded experiment.
|
|
|
(Read More | 3019 bytes | | Score: 3.66)
|
|
|
|
Posted by drstuey on Friday, August 01 2003 (3576 reads)
|
NORML News Winter 2003
The Multiple Sclerosis Society of New Zealand has welcomed news that a pioneering British cannabis-based treatment may be permitted in New Zealand.
|
|
|
(Read More | 1324 bytes | | Score: 0)
|
|
|
|
Posted by norml on Monday, June 02 2003 (3050 reads)
|
Medical marijuana is in the news again, with the Labour government making sympathetic noises and UK firm GW Pharmaceuticals launching it's medicinal cannabis spray Sativex.
Minister of Health Annette King has the power to make cannabis-based medicines such as Sativex available for prescription by doctors.
Take our poll and tell us what you think.
|
|
|
(Read More | | Score: 4)
|
|
|
|
Posted by drstuey on Thursday, May 22 2003 (4538 reads)
|
GW Pharmaceuticals, the UK research company who have successfully conducted clinical trials of their cannabis spray medicine, Sativex, have signed a deal with German drug company Bayer to market and distribute Sativex in the UK.
Bayer also has an option to market the drug in the rest of Europe as well as Canada, Australia and New Zealand. So if the government here allows it, the whole plant extract under the tongue spray could be in pharmacies soon.
Patients groups in New Zealand welcomed the move.
To make it happen, it is important that people email the Minister of Health, aking@ministers.govt.nz and tell her to look at the evidence from Britain and allow Sativex to be prescribed here.
 22/05/03 Multiple Sclerosis Group Welcomes Possibility Of Cannabis Pill
NORML In-depth: UK med-mj research
|
|
|
(Read More | 3351 bytes | | Score: 5)
|
|
|
|
Posted by drstuey on Saturday, March 22 2003 (2840 reads)
|
The Guardian, Saturday March 22, 2003
By Alan Travis, home affairs editor
The first cannabis-based prescription medicines for more than 30 years will be available in high street chemists this year, the drugs minister, Bob Ainsworth, revealed yesterday.
GW Pharmaceuticals, which was licensed by the Home Office to carry out clinical research trials on cannabis, has submitted "an extremely positive" report to the medicines control agency before final approval.
|
|
|
(Read More | 3521 bytes | | Score: 5)
|
|
|
|
Posted by drstuey on Wednesday, November 06 2002 (2795 reads)
|
The Guardian, Wednesday November 6, 2002
By Ian Griffiths
Cannabis could be available on prescription in Britain for multiple sclerosis sufferers from next year.
Results from final trials of the cannabis-based medicine developed by GW Pharmaceuticals have been much better than expected. GW will use the evidence to support an application early next year to the medicines control agency for it to go into full production.
|
|
|
(Read More | 2322 bytes | | Score: 0)
|
|
|
|
Posted by drstuey on Tuesday, November 05 2002 (2789 reads)
|
The Guardian, Tuesday November 5, 2002
By Terry Macalister
Shares in GW Pharmaceuticals, the company pioneering research into cannabis-based medicines, soared 17.5% to 151p yesterday as it prepared to announce positive trial results this morning.
The Salisbury-based business will say tests on treatments for patients with multiple scelorosis (MS) have been successful and it plans to apply for early approval to make products available to patients.
|
|
|
(Read More | 2087 bytes | | Score: 5)
|
|
|
|
Posted by drstuey on Monday, October 07 2002 (2440 reads)
|
The Independent, 07 October 2002
By Jeremy Laurance, Health Editor
Pharmaceutical companies invest millions to develop new painkillers as Medical Research Council tests enter their final phase
The world's oldest euphoric drug is poised to make a return to the medicine cabinet. Cannabis, reputedly taken by Queen Victoria to quell her period pains but banished from Britain's schedule of medicinal drugs in 1971, is on the point of winning scientific backing for its role in easing the symptoms of chronic disease.
This week the Medical Research Council is due to announce that it has recruited the last of 660 patients to a £1.2m trial of cannabis-based medicines in the treatment of multiple sclerosis, the largest in the world. Most of the patients recruited over the past two years have already completed the 15-week trial, in 30 centres round the UK.
|
|
|
(Read More | 9260 bytes | | Score: 4.5)
|
|
|
|
Posted by drstuey on Tuesday, May 21 2002 (2576 reads)
|
The Independent, 21 May 2002
By Lorna Duckworth Health Correspondent
The use of cannabis-based drugs to treat multiple sclerosis and terminal cancer moved a step closer yesterday when ministers asked for an investigation by the panel which vets medicines for the NHS.
|
|
|
(Read More | 1462 bytes | | Score: 0)
|
|
|
|
Posted by drstuey on Friday, April 12 2002 (3374 reads)
|
The Guardian, Friday April 12, 2002
By Simon Bowers
GW Pharmaceuticals, which holds the sole UK licence to develop cannabis-based medicines, yesterday doubled the number of its clinical trials to discover the medical benefits of the drug.
Four new trials of the firm's under the tongue spray will be carried out on patients with spinal cord injuries, multiple sclerosis and nerve path damage. GW hopes they will help prove the drugs can ease pain and help sleep.
|
|
|
(Read More | 1772 bytes | | Score: 0)
|
|
|
|
Posted by drstuey on Monday, January 21 2002 (2650 reads)
|
New Zealand Herald, 21.01.2002
Patients in uncontrollable pain from terminal cancer are to be
treated with cannabis-based medicines as part of British trials
launched last week.
|
|
|
(Read More | 1459 bytes | | Score: 0)
|
|
|
|
Posted by drstuey on Sunday, November 04 2001 (2580 reads)
|
The Observer, Sunday November 4, 2001
Anthony Browne, health editor
Scientific tests of 'wonder drug' give patients new hope
Cannabis is a 'wonder drug' capable of radically transforming the lives of very sick people, according to the results of the first clinical trials of the drug.
Tests sanctioned by the Government are proving far more successful than doctors, patients and cannabis campaigners ever dared hope. Some of the patients are simply calling it a 'miracle'.
|
|
|
(Read More | 4172 bytes | | Score: 4.57)
|
|
|
|
Posted by drstuey on Monday, September 10 2001 (2819 reads)
|
|
LONDON, Sept 10 (Reuters) - A British company developing the world's
first cannabis-based medicines said on Monday its under-the-tongue spray
had delivered significant benefit for 77 percent of chronic pain sufferers in
clinical trials.
|
|
|
(Read More | 2387 bytes | | Score: 0)
|
|
33 Stories (2 Pages, 20 Per Page)
[ 1 | 2 ] |
|
| | | Login |
|
You can register for some special extra features.
| |
| Arrest-o-meter |
Estimated number of cannabis offences since Labour came to power:
159043
See Details » | |
| Older Articles |
| March 25, 2000 | | · | Cannabis medical trials under way (2) |
| December 14, 1999 | | · | Clinical trial of cannabis recruits MS sufferers (2) |
| June 13, 1999 | | · | Cannabis Inhalers in First Legal Health Test (2) |
| January 23, 1999 | | · | Sowing seeds for cannabis cure-all (4) |
| January 19, 1999 | | · | Hunt for cannabis cure (3) |
| · | These women could be the first to take cannabis legally (2) |
| January 12, 1999 | | · | Doctors volunteer to test cannabis (5) |
| January 05, 1999 | | · | Secret farm harvests legal cannabis for medical trials (4) |
| December 27, 1998 | | · | Ministers Approve NHS Cannabis Tests (2) |
| December 24, 1998 | | · | Prince Ponders Medicinal Value of Cannabis (6) |
| November 12, 1998 | | · | UK: Lords' call for medical cannabis rejected (5) |
| November 11, 1998 | | · | UK: Lords Say, Legalise Cannabis for Medical Use (5) |
| July 28, 1998 | | · | Multiple Sclerosis victims to test medical effectiveness of Cannabis (5) |
| |
|
|
